{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T10:23:47Z","timestamp":1781951027775,"version":"3.54.5"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Germline epidermal growth factor receptor (EGFR) mutations have been increasingly recognized as genetic risk factors for non-small cell lung cancer (NSCLC), with T790M, V843I, and R776H constituting the mostly reported variants. The germline EGFR p848L mutation (c.2543C&gt;T, p.Pro848Leu), initially identified by de Gunst\n                      <jats:italic toggle=\"yes\">et al<\/jats:italic>\n                      as a rare germline polymorphism suppressor, presents unsolved clinical challenge due to its ambiguous association with familial NSCLC risk and lack of established therapeutic guidelines.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>We presented a case of a 57-year-old male with a family history of lung cancer. Diagnostic workup revealed squamous cell carcinoma in the right upper lobe. Genetic profiling identified a germline EGFR P848L mutation (c.2543C&gt;T, p.Pro848Leu) through next-generation sequencing. First-line chemotherapy with nab-paclitaxel\/carboplatin failed to achieve disease control. According to the RECIST 1.1 guidelines, the therapeutic effect after immunotherapy was determined to be stable disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This case highlights the clinical challenges and therapeutic implications of germline EGFR P848L mutation in lung squamous cell carcinoma. Immunotherapy demonstrated promising efficacy, suggesting potential value in this rare genetic subset. Further studies are warranted to elucidate the oncogenic role of P848L and optimize treatment strategies for patients with this germline alteration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000004845","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T01:00:09Z","timestamp":1775091609000},"page":"2929-2934","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Lung squamous cell carcinoma with germline EGFR P848L mutation: a case report"],"prefix":"10.1097","volume":"88","author":[{"given":"Motong","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9538-8452","authenticated-orcid":false,"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"R1-20260430","doi-asserted-by":"crossref","first-page":"109\u201314","DOI":"10.1007\/s12253-019-00771-5","article-title":"Spectrum of pathogenic germline mutations in Chinese lung cancer patients through next-generation sequencing","volume":"26","author":"Tian","year":"2020","journal-title":"Pathol Oncol Res"},{"key":"R2-20260430","doi-asserted-by":"crossref","first-page":"774156","DOI":"10.3389\/fonc.2021.774156","article-title":"Identification of the unique clinical and genetic features of chinese lung cancer patients with EGFR germline mutations in a large-scale retrospective study","volume":"11","author":"Lin","year":"2021","journal-title":"Front Oncol"},{"key":"R3-20260430","doi-asserted-by":"crossref","first-page":"10086","DOI":"10.1038\/ncomms10086","article-title":"Patterns and functional implications of rare germline variants across 12 cancer types","volume":"6","author":"Lu","year":"2015","journal-title":"Nat Commun"},{"key":"R4-20260430","first-page":"662\u201367","article-title":"Fluorometric detection of low-abundance EGFR exon 19 deletion mutation using tandem gene amplification","volume":"30","author":"Kim","year":"2020","journal-title":"J Microbiol Biotechnol"},{"key":"R6-20260430","doi-asserted-by":"crossref","first-page":"1233\u201337","DOI":"10.3892\/ol.2011.366","article-title":"Mutations of the epidermal growth factor receptor gene in NSCLC patients","volume":"2","author":"Han","year":"2011","journal-title":"Oncol Lett"},{"key":"R7-20260430","first-page":"390\u201392","article-title":"Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients","volume":"23","author":"Prim","year":"2014","journal-title":"Eu Respir Rev"},{"key":"R8-20260430","doi-asserted-by":"crossref","first-page":"1689\u2013704","DOI":"10.1002\/2211-5463.12702","article-title":"Characterization of epidermal growth factor receptor (EGFR) P848L, an unusual EGFR variant present in lung cancer patients, in a murine Ba\/F3 model","volume":"9","author":"Sarcar","year":"2019","journal-title":"FEBS Open Bio"},{"key":"R9-20260430","doi-asserted-by":"crossref","first-page":"186\u201387","DOI":"10.1016\/j.lungcan.2022.09.005","article-title":"Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report","volume":"174","author":"Trabelsi Grati","year":"2022","journal-title":"Lung Cancer"},{"key":"R10-20260430","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.12.012","article-title":"Decoding the clinical and molecular signatures of EGFR common, compound, and uncommon mutations in NSCLC: a brief report","author":"Tavernari","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:00:15Z","timestamp":1777554015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MS9.0000000000004845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000004845","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"2025-08-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-21","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}